Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2995906 | 1.00 | NR1H2 (0.43) | NR1H2HPGDDDB1CRBNMEN1 | |
| SCHEMBL2285980 | 0.89 | HPGD (0.51) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2285975 | 0.89 | HPGD (0.51) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL30364451 | 0.86 | MEN1 (0.54) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL21348930 | 0.86 | MEN1 (0.54) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL19194947 | 0.86 | MEN1 (0.54) | HPGDMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL16827771 | 0.85 | HPGD (0.54) | HPGDMAPTKMT2AUSP2SMN1; SMN2 | |
| SCHEMBL29569186 | 0.85 | NR1H2 (0.41) | NR1H2HPGDDDB1CRBNMAPT | |
| SCHEMBL16827768 | 0.85 | HPGD (0.54) | HPGDMAPTKMT2AUSP2SMN1; SMN2 | |
| SCHEMBL18418139 | 0.85 | NR1H2 (0.41) | NR1H2HPGDDDB1CRBNMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298163-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BEIGENE, LTD. (KY) | 2022-09-22 | — | — | US | disclosed |
| US-11377449-B2 | BTK inhibitors with improved dual selectivity | BEIGENE, LTD. (KY) | 2022-07-05 | — | — | US | disclosed |
| CN-112707893-A | 1-cyanopyrrolidine compounds as USP30 inhibitors | 特殊治疗有限公司 | 2021-04-27 | — | — | CN | disclosed |
| CN-107484415-B | 1-cyanopyrrolidine compounds as USP30 inhibitors | 特殊治疗有限公司 | 2021-01-29 | — | — | CN | disclosed |
| US-20200181150-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BEONE MEDICINES I GMBH (CH) | 2020-06-11 | — | — | US | disclosed |
| US-20140088081-A1 | Amino-Heterocyclic Compounds | PFIZER INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8618117-B2 | Amino-heterocyclic compounds | PFIZER INC. (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2389382-B1 | Amino-heterocyclic compounds used as pde9 inhibitors | PFIZER (US) | 2013-06-05 | — | — | EP | disclosed |
| US-20120329777-A1 | Amino-Heterocyclic Compounds | PFIZER INC. | 2012-12-27 | — | — | US | disclosed |
| US-8278295-B2 | Amino-heterocyclic compounds | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298163-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BTK, SYK, LYN | NR1H2 3029/4885HPGD 4702/4885DDB1 908/4885 |
| US-20200181150-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BTK, SYK, LYN | NR1H2 3029/4885HPGD 4702/4885DDB1 908/4885 |
| US-11377449-B2 | BTK inhibitors with improved dual selectivity | BTK, SYK, LYN | NR1H2 3029/4885HPGD 4702/4885DDB1 908/4885 |
| US-20120329777-A1 | Amino-Heterocyclic Compounds | PDE9A, PDE2A, PDE10A | NR1H2 2730/4885HPGD 1306/4885DDB1 4011/4885 |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PDE9A, PDE2A, PDE10A | NR1H2 2730/4885HPGD 1306/4885DDB1 4011/4885 |
| US-20140088081-A1 | Amino-Heterocyclic Compounds | PDE9A, PDE2A, PDE10A | NR1H2 2730/4885HPGD 1306/4885DDB1 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.